Tumorigenesis
Return to Library
|
Free Tumorigenesis Articles |
|
|
|
|
Reports from R. Martinezmurillo et al highlight recent research in glioblastoma
2007 NOV 19 -- According to recent research published in the journal Histology and Histopathology, "Animal models of glial-derived neoplasms are needed to study the biological mechanisms of glioma tumorigenesis and those that sustain the disease state. With the aim to develop and characterize a suitable in vivo experimental mouse model for infiltrating astrocytoma, with predictable and reproducible growth patterns that recapitulate human astrocytoma, this study was undertaken to analyze the long-term course of a syngeneic orthotopically implanted CT-2A mouse astrocytoma in C57BL/6J mice." "Intracranial injection of CT-2A cells into caudate-putamen resulted in development of an aggressive tumor showing typical features of human glioblastoma multiforme, sharing close histological, immunohistochemical, proliferative, and metabolic profiles. To simulate metastatic disease to the brain, CT-2A cells were injected through the internal carotid artery. Tumors identical to those obtained by intracranial injection were obtained. Finally, CT-2A cells were re-isolated from experimental brain tumors and transcranially re-injected into the caudate-putamen of healthy mice. These cells generated new tumors that were indistinguishable from the initial ones, suggesting in vivo self-renewal of tumor cells. Small-animal models are essential for testing novel biological therapies directed against relevant molecular targets. In a preliminary study, experimental CT-2A tumors were chronically treated with the small molecule 77427, a gastrin-releasing peptide (GRP) blocker compound that inhibits angiogenesis. Treated animals developed significantly smaller tumors than controls, suggesting an antitumor action for 77427 in glioblastomas," wrote R. Martinezmurillo and colleagues. The researchers concluded: "We conclude that the orthotopic CT-2A tumor model, as described herein, is appropriate to explore the mechanisms of glioma development and for preclinical trials of promising drugs." Martinezmurillo and colleagues published their study in Histology and Histopathology (Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. Histology and Histopathology, 2007;22(12):1309-1326). For additional information, contact A. Martinez, CSIC, Institute Cajal, Dept. of Molecular Cellular & Development Neurobiology, Avda Doctor Arce 37, E-28002 Madrid, Spain. The publisher's contact information for the journal Histology and Histopathology is: F Hernandez, Plaza Fuensanta 2-7 C, 30008 Murcia, Spain. Keywords: Spain, Madrid, Glioblastoma, Oncology. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2007, Clinical Oncology Week via NewsRx.com.
|
